Roche’s Tecentriq meets primary endpoints in Phase III lung cancer trial

Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall survival compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer.
read more http://www.pharmafile.com/news/506950/roche-s-tecentriq-meets-primary-endpoints-phase-iii-lung-cancer-trial